Shots:
- The Genentech‘s P-III (METEOROID) trial data assessed Enspryng (60, 120 or 180mg based on body weight; SC) vs PBO, administered at 0, 2 & 4wks., then Q4W thereafter in pts (≥12yrs.) with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
- Trial met its 1EP with 87% vs 67% relapse-free pts at 48wks., & response onset as early as 8wks.; results were consistent effects across subgroups. Trial also showed a 66% reduction in annualized relapse rate (2EP)
- Other key 2EPs showed a 79% reduction in the annualized rate of MRI-detected active lesions across the optic nerves, brain & spinal cord, a 73% lower need for rescue therapy, & a 17% numerical reduction in annualized inpatient hospitalizations. Results were presented at AAN’26 & will be shared with regulators globally
Ref: Businesswire | Image: Genentech |Press Release
Related News: Genentech Reports P-III (MAJESTY) Trial Results for Gazyva in Primary Membranous Nephropathy
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
